14 results about "Azoospermatism" patented technology

The invention relates to the technical field of biological medicines, in particular to an umbilical cord mesenchymal stem cell exosome and application of the umbilical cord mesenchymal stem cell exosome in preparation of a medicine for treating male infertility caused by hidden testis. The prepared high-concentration umbilical cord mesenchymal stem cell exosome suspension preparation is directly used for treating cultured spermatogonial cells and spermatoblasts in vitro, is injected into the testis of a mouse, and is used for improving the seminiferous tubule and spermatogenic microenvironment of testis tissue and promoting division and proliferation of the spermatogonial cells and the spermatoblasts. The method can effectively reverse oligospermia and azoospermia caused by the hidden testis, and compared with a model without intervention of treatment means, the method can effectively promote increase and even regeneration of sperms in the testis.

The invention relates to the technical field of reproductive medicine, in particular to a high-quality sperm acquisition method based on a testis tissue sample of an azoospermia patient, which comprises the following steps: inputting a first frame of a testis tissue sample microscopic video sequence into a target detection model, outputting a sperm detection frame and confidence, and taking the position of the detection frame as a starting point of a motion trail; a dynamic confidence matching strategy is adopted, firstly, a prediction trajectory is matched with a high-confidence detection result, then, a real leak detection target is complemented with a low-confidence target, multi-stage Hungary matching is achieved through confidence guidance, and all sperm movement trajectories obtained in each frame are obtained; and based on multiple frames of images corresponding to all sperm movement tracks corresponding to the microscopic video sequence, selecting the multiple frames of images according to a preset number of confidence coefficients to construct a candidate morphological analysis sample set, and performing kinematics parameter calculation and morphological analysis to obtain high-quality target sperms. According to the method, the recognition efficiency of high-quality sperms is improved, the sperms with higher quality can be obtained, and the subsequent fertilization success rate is further improved.

This invention provides a biomarker for spermatogenesis disorders and its application, wherein the biomarker is the MNDA molecule. This application characterizes the functional abnormalities or spermatogenesis disorders of Sertoli cells by detecting the expression level of MNDA molecules on cells in testicular tissue sections, and can therefore be used for the clinical diagnosis of non-obstructive azoospermia.

The invention discloses a method for distinguishing obstructive azoospermia and non-obstructive azoospermia based on ultrasonic images and machine learning, and relates to the technical field of image analysis and machine learning, all patients are subjected to bilateral scrotum ultrasonic examination before operation; patients are divided into a training set, a validation set, and a test set according to the use of the dataset. In the training set, image omics features are extracted from the left testis ultrasonic image and the right testis ultrasonic image, and key features related to obstructive azoospermia are screened out; on the basis of the selected radiomics features, five machine learning models are constructed, including a k-nearest neighbor model, a logistic regression model, a multi-layer perceptron model, a random forest model and a support vector machine model; analyzing and evaluating the diagnostic performance and clinical application value of the model in the three groups of data through an ROC curve and a clinical decision curve; and explaining the final machine learning model by using SHAP analysis. The method has important value in distinguishing obstructive azoospermia and non-obstructive azoospermia, wherein the logistic regression model shows better diagnostic performance compared with other four models.

The invention discloses a method for constructing an azoospermia mouse model by knocking out a germ cell Rbbp6 gene and application of the azoospermia mouse model, the construction method is to knock out the Rbbp6 gene on a mouse germ cell genome, and the knockout is carried out by using a Cre-LoxP system. The azoospermia mouse model constructed by the invention can be used for research on non-obstructive azoospermia and corresponding drug research and development. The model mouse shows that the testis weight and volume are reduced, spermatogenic epithelium atrophy, a large number of germ cells are deleted, and the number of sperms is reduced.

The invention discloses a new application of lenalidomide (CC-5013) in the treatment of male oligospermia and azoospermia caused by hepatitis E virus (HEV) infection or the improvement of sperm quality, and particularly discloses a new application of lenalidomide (CC-5013) in the treatment of male oligospermia and azoospermia caused by hepatitis E virus (HEV) infection. The lenalidomide is proved to have an obvious treatment effect on sperm quality reduction caused by HEV infection through sperm staining, sperm motility detection, testis pathology analysis, quantitative detection of sperm development key genes and other methods by utilizing an HEV infected mouse model. The treatment scheme provided by the invention is safe and effective, good in treatment effect and low in medicine cost, is suitable for rapid treatment of male reproductive injuries such as male azoospermia, oligospermia and poor sperm quality caused by virus infection, and provides medicine support for diagnosis and treatment of male infertility patients caused by HEV infection.

The invention discloses a method for constructing an azoospermia mouse model by knocking out a UBC9 gene of a germ cell and application of the azoospermia mouse model, the construction method is to knock out the UBC9 gene on a mouse germ cell genome, and the knockout is carried out by using a Cre-LoxP system. The azoospermia mouse model constructed by the invention can be used for research on non-obstructive azoospermia and corresponding drug research and development. The model mouse shows that the testis weight and volume are reduced, a large number of germ cells are deleted, meiosis is stopped, and mature sperms are completely deficient.

The invention discloses a method for constructing an azoospermia mouse model by knocking out a germ cell EIF5A gene and application of the azoospermia mouse model, the construction method is to knock out the EIF5A gene on a mouse germ cell genome, and the knockout is carried out by using a Cre-LoxP system. The azoospermia mouse model constructed by the invention can be used for research on non-obstructive azoospermia and corresponding drug research and development. The model mouse shows that the testis weight and volume are reduced, the spermatogenic epithelium is atrophic, spermatogonium cells cannot complete meiosis completely, germ cells are massively deleted, and the sperm quantity is reduced.

The invention discloses a method for constructing an azoospermia mouse model by knocking out a germ cell Sno1 gene and application of the azoospermia mouse model, the construction method is to knock out the Sno1 gene on a mouse germ cell genome, and the knockout is carried out by using a Cre-LoxP system. The azoospermia mouse model constructed by the invention can be used for research on non-obstructive azoospermia and corresponding drug research and development. The model mouse shows that the testis weight and volume are reduced, spermatogenic epithelium atrophy occurs, spermatogonium cells do not enter meiosis, germ cells are massively deleted, and the number of sperms is reduced.

The invention provides a dyszoospermia biomarker and an application thereof. The biomarker is an MNDA molecule. According to the application, the state of dysfunction or dyszoospermia of Sertoli cells is represented by detecting the expression level of MNDA molecules on cells in a testicular tissue slice, so that the application can be used for clinical diagnosis and the like of non-obstructive azoospermia.

The invention provides a stepped azoospermia diagnosis and treatment decision support system based on deep learning, and relates to the technical field of diagnosis and treatment decision systems. Comprising a first stage of clinical decision enhancement type TabTransform and a second stage of multi-task perception type TabTransform. In the first stage, a sperm extraction result is predicted based on clinical data, a sperm extraction success rate is predicted, an operation is recommended when the success rate is higher than a threshold value, and an operation decision is given; otherwise, triggering the second stage, introducing high-dimensional gene data deep analysis, and accurately predicting the disease subtype. According to the system, through a progressive data integration mechanism, intelligent transition from preliminary screening to precise typing is achieved, and the pain point problems that in a traditional diagnosis and treatment system, single-dimensional data prediction is achieved, the diagnosis and treatment process is fragmented, and clinical doctors have no quantitative standards for diagnosis and are too subjective and one-sided are effectively solved. The scientificity and the consistency of operation decisions are kept, and a scientific basis is provided for a subsequent personalized treatment scheme.

The invention discloses application of a gene knockout animal model in male sterility research, and belongs to the technical field of transgenosis. The invention provides a construction method of an azoospermia mouse model, the construction method is characterized in that an MTR4 gene on a mouse genome is knocked out, and the knockout is carried out by utilizing CRISPR / Cas (Clustered Regularly Interspaced Short Palindromic Repeats / Cass). The important function of the MTR4 gene in the spermatogenesis process of mice is disclosed for the first time, testis dysplasia and azoospermia occur in male mice with MTR4 knockout, and a testis development regulation mechanism of MTR4 is expected to provide a new thought for research of a male infertility mechanism.

The present invention provides a male infertility classification method and device and a method and device for constructing a related prediction model. The classification method comprises: using a contribution proportion of testis-related single-cell types in seminal plasma cell-free RNA as a feature to construct a male infertility prediction model; and inputting the contribution proportion of the testis-related single-cell types in the seminal plasma cell-free RNA of a sample to be tested into the male infertility prediction model to obtain a classification prediction result of the sample to be tested. The classification method can accurately predict male azoospermia and subtypes thereof of an unknown sample, and is more convenient to operate compared with a previous method. In addition, the method allows for prediction of the subtypes of azoospermia prior to clinical testicular biopsy, thereby achieving the objectives of non-invasive detection and diagnosis.